4-(4-BROMPHENYL)-1-[1-(2-HYDROXYPHENYL)-3-(4-HYDROXYPHENYL)ALLYLIDENE]SEMICARBAZIDE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KPDPKBBTNJGGNZ-SIACRCKJSA-N
Smiles	Oc1ccc(\C=C\C(=N/NC(=O)Nc2ccc(Br)cc2)\c3ccccc3O)cc1
InChI	InChI=1S/C22H18BrN3O3/c23-16-8-10-17(11-9-16)24-22(29)26-25-20(19-3-1-2-4-21(19)28)14-7-15-5-12-18(27)13-6-15/h1-14,27-28H,(H2,24,26,29)/b14-7+,25-20+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H18BrN3O3
Molecular Weight	452.3
AlogP	4.97
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	5.0
Polar Surface Area	93.95
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	29.0

Assay Description	Organism	Bioactivity	Reference
Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against maximal electroshock-induced seizures at 30 mg/kg, ip administered 30 min prior to electro shock-challenge measured for 2 min relative to phenytoin	Mus musculus	84.95 %
Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against maximal electroshock-induced seizures at 30 mg/kg, ip administered 30 min prior to electro shock-challenge measured for 2 min relative to control	Mus musculus	67.92 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2234149

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).